Reporting of Post-protocol Therapies in Metastatic Breast Cancer Registration Clinical Trials: A Systematic Review

The treatment for metastatic breast cancer (MBC) is constantly evolving, with 36 new indications for 18 different drugs approved by the US FDA in the last decade [1]. Clinical trials are vital for exploring new therapies and improving patient outcomes. Patients with MBC are usually treated with multiple sequential lines of therapy[2]. Often, there is no consensus regarding optimal sequencing of treatment, leading to potential variation in post-protocol therapies of patients following progression on clinical trials.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Systematic or Meta-analysis Studies Source Type: research